샘플 요청 목록

 카트 문의
시장보고서
상품코드
2143603

C형 간염 치료 시장

Hepatitis C Treatment
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 468 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,914,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 15,037,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,743,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 C형 간염 치료 시장은 2032년까지 121억 달러에 이를 전망입니다.

2025년에 95억 달러로 평가된 세계의 C형 간염 치료 시장은 2032년까지 121억 달러에 이른다고 전망되고 2025년부터 2032년까지 분석 기간에 CAGR 3.5%를 나타낼 것으로 예측됩니다. 본 보고서로 분석 대상이 되고 있는 부문 중 하나인 ' 직접 작용 형항바이러스제(DAA) 치료 '는 CAGR 4.2%를 나타내고, 분석 기간 종료까지 47억 달러에 이를 것으로 예상되고 있습니다. 또한 ' 인터페론계 치료 ' 부문의 성장률은 분석 기간 동안 CAGR 3.9%로 추정되고 있습니다.

미국 시장은 26억 달러로 평가되는 한편, 중국은 CAGR 6.2%를 나타낼 것으로 예측됩니다.

2025년 미국의 C형 간염 치료 시장 규모는 26억 달러로 평가되었습니다. 세계 제2위 경제 규모를 자랑하는 중국에 대해는 2025년부터 2032년까지 CAGR 6.2%로 성장을 지속하여, 2032년까지 시장 규모가 24억 달러에 이를 것으로 예측됩니다. 기타 주목해야 할 지역 시장으로서는 일본과 캐나다를 들 수 있어 분석 기간 중에 각각 CAGR 1.6% 및 2.8%를 나타낼 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 2.2%를 나타낼 것으로 예측됩니다.

세계의 C형 간염 치료 시장 - 주요 시장 동향 및 성장 촉진요인 개요

C형 간염 치료 분야의 최신 발전 동향은 무엇인가?

주로 간에 영향을 미치는 바이러스 감염증인 C형 간염 치료 분야에서는 획기적인 진전이 나타나고 있습니다. 기존의 치료법에는 심각한 부작용을 동반하는 경우가 많고, 완치율에도 편차가 있었던 장기적인 인터페론 요법이 포함되어 있었습니다. 그러나 직접 작용 항바이러스제(DAA)의 등장으로 C형 간염 치료는 혁명적인 변화를 맞이했습니다. 소포스부비르, 레디파스비르, 다크라타스비르 등의 이러한 DAA는 C형 간염 바이러스의 생애 주기 중 특정 단계를 표적으로 삼아, 치료 기간 단축과 부작용 경감을 실현하면서 95% 이상의 완치율을 보여주고 있습니다. 치료 요법의 간소화와 범유전자형 DAA의 도입으로 치료 접근성이 더욱 확대되어, 더 폭넓은 환자층을 효과적으로 치료할 수 있게 되었습니다.

새로운 치료법은 환자의 예후를 어떻게 개선하고 있는가?

새로운 치료법의 도입으로 C형 간염 관리에 있어 환자의 예후가 현저히 개선되었습니다. DAA는 최장 1년까지 소요되기도 했던 기존의 인터페론 기반 치료와 비교하여 치료 기간이 대폭 단축되어, 대부분의 경우 단 8-12주면 충분합니다. 이러한 치료 기간 단축과 DAA의 부작용이 최소화되었습니다는 점이 결합되어, 환자의 복약 순응도와 전반적인 치료 경험이 크게 향상되었습니다. 또한, 이러한 치료법은 초기 섬유화부터 진행된 간경변에 이르기까지 간 질환의 모든 단계에서 효과가 입증되었습니다. DAA의 높은 치료 성공률은 간암이나 간부전과 같은 C형 간염 관련 합병증의 현저한 감소에도 기여하고 있으며, 이를 통해 환자의 장기적인 건강 예후가 개선되고 있습니다.

왜 전 세계적으로 C형 간염 치료에 대한 접근성이 확대되고 있는가?

전 세계적으로 C형 간염 치료에 대한 접근성이 크게 확대된 것은 정책적 노력, 제네릭 의약품 생산, 그리고 국제적 협력이 어우러진 결과였습니다. 많은 국가에서는 모든 감염자를 진단하고 치료하는 것을 목표로 하는 국가 차원의 C형 간염 퇴치 프로그램을 시행하고 있습니다. DAA 제네릭 의약품의 생산으로 치료비가 대폭 절감되어, 저·중소득 국가에서도 합리적인 가격으로 치료가 가능해졌습니다. 또한, 제약 회사, 정부, 비정부기구(NGO) 간의 협력을 통해 대규모 치료 프로그램과 인식 제고 캠페인이 촉진되고 있습니다. 이러한 노력은 2030년까지 C형 간염을 공중보건상의 위협으로 근절하겠다는 세계보건기구(WHO)의 목표에 힘입어 전 세계적으로 검사 및 치료 활동이 광범위하게 추진되고 있습니다.

시장 성장의 주요 촉진요인은 무엇인가?

C형 간염 치료 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 약제 제형 및 약물 전달 기술의 발전으로 치료 효과와 환자의 복약 순응도가 향상되었습니다. 특히 고위험군에서 C형 간염 유병률이 증가함에 따라 효과적인 치료법에 대한 수요가 높아지고 있습니다. 진단 기술의 향상과 광범위한 선별 검사 프로그램 덕분에 조기 발견과 신속한 개입이 가능해졌으며, 치료 선택의 폭이 넓어지고 있습니다. 신규 및 개량된 직접작용형 항바이러스제(DAA)에 대한 규제 당국의 승인뿐만 아니라, 제약 기업의 연구 개발에 대한 적극적인 투자가 시장 확장을 뒷받침하고 있습니다. C형 간염 근절을 위한 공중보건 정책과 국제적인 노력 또한 시장 성장에 크게 기여하고 있습니다. 또한, 정부, 의료 서비스 제공업체, 제약 기업을 포함한 이해관계자간의 협력은 혁신을 촉진하고 첨단 치료법의 제공을 가속화하고 있습니다. 이러한 요인들이 결합되어 역동적이고 급속히 진화하는 C형 간염 치료 시장을 견인하고 있습니다.

부문 :

치료법(직접 작용 형항바이러스제(DAA)에 의한 치료, 인터페론 기반 치료, 지지 요법/보조 요법, 기타 치료법), 적응증(전유전자형 적응, 유전자형 특이적 적응, 급성기 적응, 만성기 적응, 소아 적응, 성인 적응), 유통 채널(공중위생 프로그램 및 입찰에 의한 유통 채널, 병원 및 전문 클리닉에 의한 유통 채널, 기타 유통 채널)

주요 기업

  • AbbVie, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson &Johnson
  • Kadmon Holdings, Inc.
  • Merck &Co., Inc.

해당 분야의 전문가들의 관점을 바탕으로 합니다.. 산업계, 기업, 학계에 걸쳐 있는 분야 전문가들의 관점을 반영하여, 기존에 발표된 조사 결과 이상의 맥락을 제공합니다.

시장의 초기 신호를 포착합니다. - 기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다-컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업 공시 정보, 연차 보고서, 기관 간행물 및 기타 검증된 정보원에서 얻은 인사이트를 통합합니다.

신호와 전략적 시장 방향성을 연결합니다. - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있어 가장 중요할 가능성이 높은 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다. - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 기여하고 있는 기업을 상세하게 검증합니다.

주요 지역 시장 점유율을 면밀히 검토합니다. - 단일 세계 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구도는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서에서는 각 시장의 구조와 동향에 맞추어 상세한 수준으로 주요 지역 시장 점유율 분석을 전개합니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KTH

Global Hepatitis C Treatment Market to Reach US$12.1 Billion by 2032

The global market for Hepatitis C Treatment estimated at US$9.5 Billion in the year 2025, is expected to reach US$12.1 Billion by 2032, growing at a CAGR of 3.5% over the analysis period 2025-2032. Direct-Acting Antivirals Treatment, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the Interferon-based Treatment segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 6.2% CAGR

The Hepatitis C Treatment market in the U.S. is estimated at US$2.6 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2032 trailing a CAGR of 6.2% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Hepatitis C Treatment Market - Key Trends & Drivers Summarized

What Are the Latest Breakthroughs in Hepatitis C Treatment?

Hepatitis C, a viral infection that primarily affects the liver, has witnessed transformative advancements in its treatment landscape. Historically, treatment regimens included lengthy interferon-based therapies that often came with severe side effects and variable success rates. However, the advent of direct-acting antivirals (DAAs) has revolutionized hepatitis C treatment. These DAAs, such as Sofosbuvir, Ledipasvir, and Daclatasvir, target specific steps in the hepatitis C virus lifecycle, leading to cure rates exceeding 95% with shorter treatment durations and fewer side effects. The simplification of treatment regimens and the introduction of pangenotypic DAAs have further expanded treatment accessibility, making it feasible to treat a broader range of patients effectively.

How Are New Therapies Improving Patient Outcomes?

The implementation of new therapies has significantly improved patient outcomes in hepatitis C management. DAAs offer a much shorter treatment duration, often just 8 to 12 weeks, compared to the previous interferon-based treatments that could last up to a year. This reduction in treatment time, combined with the minimal side effects of DAAs, has greatly enhanced patient adherence and overall experience. Moreover, these therapies have proven effective across all stages of liver disease, from early-stage fibrosis to advanced cirrhosis. The high efficacy rates of DAAs have also contributed to a marked decrease in hepatitis C-related complications, such as liver cancer and liver failure, thereby improving long-term health outcomes for patients.

Why Is Global Access to Hepatitis C Treatment Expanding?

Global access to hepatitis C treatment has expanded significantly due to a combination of policy initiatives, generic drug production, and international collaborations. Many countries have implemented national hepatitis C elimination programs, aiming to diagnose and treat all infected individuals. The production of generic versions of DAAs has drastically reduced the cost of treatment, making it affordable for low- and middle-income countries. Additionally, collaborations between pharmaceutical companies, governments, and non-governmental organizations have facilitated large-scale treatment programs and awareness campaigns. These efforts are supported by the World Health Organization's goal to eliminate hepatitis C as a public health threat by 2030, driving widespread testing and treatment initiatives globally.

What Are the Key Drivers of Market Growth?

The growth in the hepatitis C treatment market is driven by several factors. Technological advancements in drug formulation and delivery have enhanced treatment efficacy and patient compliance. The increasing prevalence of hepatitis C, particularly among high-risk populations, has escalated the demand for effective treatments. Enhanced diagnostic techniques and widespread screening programs enable early detection and prompt intervention, broadening the treatment landscape. Regulatory approvals of new and improved DAAs, coupled with robust investment in research and development by pharmaceutical companies, fuel market expansion. Public health initiatives and international efforts to eliminate hepatitis C also significantly contribute to market growth. Additionally, partnerships between stakeholders, including governments, healthcare providers, and pharmaceutical companies, foster innovation and accelerate the availability of advanced treatment options. These factors collectively drive the dynamic and rapidly evolving hepatitis C treatment market.

SCOPE OF STUDY:

The report analyzes the Hepatitis C Treatment market by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment, Other Treatments); Indication (Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication, Adult Indication); Distribution Channel (Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • AbbVie, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Kadmon Holdings, Inc.
  • Merck & Co., Inc.

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • Hepatitis C Treatment - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 123 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Introduction of Direct-Acting Antivirals (DAAs)
    • High Cure Rates with Shorter Treatment Durations
    • Increasing Screening and Diagnosis Rates
    • Rising Awareness and Government Initiatives
    • Development of Pangenotypic Regimens
    • Growing Focus on HCV Elimination Programs
    • Advancements in Liver Disease Management
    • Increasing Investment in R&D Activities
    • Expanding Access to Healthcare in Developing Regions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hepatitis C Treatment Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for Hepatitis C Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 3: World Historic Review for Hepatitis C Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 4: World 13-Year Perspective for Hepatitis C Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Direct-Acting Antivirals Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Direct-Acting Antivirals Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Direct-Acting Antivirals Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Interferon-based Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Interferon-based Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Interferon-based Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Supportive / Adjunct Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Supportive / Adjunct Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Supportive / Adjunct Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Pan-Genotypic Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Pan-Genotypic Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Pan-Genotypic Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Genotype-Specific Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Genotype-Specific Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Genotype-Specific Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Acute Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Acute Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Acute Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Chronic Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Chronic Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Chronic Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Pediatric Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Pediatric Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Pediatric Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Adult Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Adult Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Adult Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 35: World Recent Past, Current & Future Analysis for Public Health Programs & Tenders Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 36: World Historic Review for Public Health Programs & Tenders Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: World 13-Year Perspective for Public Health Programs & Tenders Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 38: World Recent Past, Current & Future Analysis for Hospitals & Specialty Clinics Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 39: World Historic Review for Hospitals & Specialty Clinics Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: World 13-Year Perspective for Hospitals & Specialty Clinics Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 41: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 42: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: World 13-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 45: USA Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: USA 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 47: USA Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 48: USA Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: USA 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 50: USA Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 51: USA Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: USA 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 54: Canada Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: Canada 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 57: Canada Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: Canada 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 60: Canada Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: Canada 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • JAPAN
    • Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 63: Japan Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: Japan 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 66: Japan Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: Japan 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 69: Japan Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: Japan 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • CHINA
    • Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: China Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: China 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 74: China Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 75: China Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: China 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 77: China Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 78: China Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: China 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • EUROPE
    • Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Hepatitis C Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 81: Europe Historic Review for Hepatitis C Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: Europe 13-Year Perspective for Hepatitis C Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: Europe Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: Europe 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: Europe Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: Europe 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: Europe Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: Europe 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • FRANCE
    • Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: France Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: France 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 95: France Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 96: France Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: France 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 98: France Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: France Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: France 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • GERMANY
    • Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Germany Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Germany 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Germany Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: Germany 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 108: Germany Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: Germany 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: Italy Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: Italy 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: Italy Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: Italy 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: Italy Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: Italy 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: UK Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: UK 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 122: UK Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: UK Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: UK 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 125: UK Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: UK Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: UK 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Spain Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: Spain 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Spain Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Spain 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Spain Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Spain 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Russia Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Russia 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Russia Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Russia 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Russia Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: Russia 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: Rest of Europe 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: Rest of Europe 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: Rest of Europe 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis C Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Hepatitis C Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: Asia-Pacific 13-Year Perspective for Hepatitis C Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: Asia-Pacific 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: Asia-Pacific 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: Asia-Pacific 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: Australia Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: Australia 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 171: Australia Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: Australia 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: Australia Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: Australia 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • INDIA
    • Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 176: India Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: India Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: India 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 179: India Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: India Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: India 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 182: India Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: India Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: India 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: South Korea Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: South Korea 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: South Korea Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: South Korea 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 192: South Korea Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: South Korea 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Hepatitis C Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 204: Latin America Historic Review for Hepatitis C Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: Latin America 13-Year Perspective for Hepatitis C Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Latin America Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Latin America 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Latin America Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Latin America 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Latin America Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Latin America 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Argentina Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 217: Argentina 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Argentina Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 220: Argentina 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Argentina Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 223: Argentina 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Brazil Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 226: Brazil 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 228: Brazil Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 229: Brazil 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 231: Brazil Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 232: Brazil 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 234: Mexico Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 235: Mexico 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 237: Mexico Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 238: Mexico 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 240: Mexico Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 241: Mexico 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 244: Rest of Latin America 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 247: Rest of Latin America 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 250: Rest of Latin America 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Hepatitis C Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 252: Middle East Historic Review for Hepatitis C Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 253: Middle East 13-Year Perspective for Hepatitis C Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Middle East Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 256: Middle East 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Middle East Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 259: Middle East 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Middle East Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 262: Middle East 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Iran Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 265: Iran 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Iran Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 268: Iran 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Iran Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 271: Iran 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Israel Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 274: Israel 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Israel Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 277: Israel 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 279: Israel Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 280: Israel 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 283: Saudi Arabia 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 286: Saudi Arabia 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 289: Saudi Arabia 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 291: UAE Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 292: UAE 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 294: UAE Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 295: UAE 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 297: UAE Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 298: UAE 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 301: Rest of Middle East 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 304: Rest of Middle East 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 307: Rest of Middle East 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • AFRICA
    • Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 309: Africa Historic Review for Hepatitis C Treatment by Treatment - Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 310: Africa 13-Year Perspective for Hepatitis C Treatment by Treatment - Percentage Breakdown of Value Sales for Direct-Acting Antivirals Treatment, Interferon-based Treatment, Supportive / Adjunct Treatment and Other Treatments for the Years 2020, 2026 & 2032
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 312: Africa Historic Review for Hepatitis C Treatment by Indication - Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 313: Africa 13-Year Perspective for Hepatitis C Treatment by Indication - Percentage Breakdown of Value Sales for Pan-Genotypic Indication, Genotype-Specific Indication, Acute Indication, Chronic Indication, Pediatric Indication and Adult Indication for the Years 2020, 2026 & 2032
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 315: Africa Historic Review for Hepatitis C Treatment by Distribution Channel - Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 316: Africa 13-Year Perspective for Hepatitis C Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Public Health Programs & Tenders Distribution Channel, Hospitals & Specialty Clinics Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기